SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

DATE OF REPORT – December 16, 2008

(Date of Earliest Event Reported)

COLUMBIA LABORATORIES, INC.

(Exact name of registrant as specified in its charter)

Commission File No.  1-10352

Delaware	59-2758596
(State of Incorporation)	(I.R.S. Employer       Identification No.)
354 Eisenhower Parkway Livingston, New Jersey	07039
(Address of principal       executive offices)	Zip Code

Registrant’s telephone number, including area code:  (973) 994-3999

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02(d)  Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On December 16, 2008, the Board of Directors of Columbia Laboratories, Inc. (the “Company”) increased the size of the Board from seven to eight directors and elected Anthony R. Campbell as a director to fill the newly created seat and to serve on the Board’s Audit and Scientific Committees. The Board also (i) granted to Mr. Campbell 20,833 shares of restricted stock pursuant to the Company’s compensation and reimbursement practices for non-employee directors filed as an exhibit to the Company’s quarterly report on Form 10-Q, dated August 8, 2007, and subject to a restricted stock agreement substantially in the form filed as an exhibit to the Company’s current report on Form 8-K, dated May 17, 2006, and (ii) agreed that the Company will enter into an indemnification agreement with Mr. Campbell substantially in the form filed as an exhibit to the Company’s annual report on Form 10-K for the year ended December 31, 2003.

The Company is not aware of (i) any arrangement or understanding between the new director and any other persons pursuant to which he was selected as a director or (ii) any item requiring disclosure under Item 404(a) of Regulation S-K.

Item 8.01 Other Events

On December 17, 2008, the Company issued a press release about the election of Mr. Campbell to the Board. A copy of Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by reference.

Item 9.01                      Financial Statements and Exhibits.

 (d)           Exhibits.

Exhibit No.	Description
99.1	Press Release dated December 17, 2008, entitled: “Anthony R. Campbell Elected to Columbia Laboratories Board of Directors.”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date:  December 19, 2008

COLUMBIA LABORATORIES, INC.

By: /S/ James A. Meer

James A. Meer

Senior Vice President

and Chief Financial Officer

Exhibit Index

Exhibit No.	Description
99.1	Press Release dated December 17, 2008, entitled: “Anthony R. Campbell Elected to Columbia Laboratories Board of Directors.”